Additionally, Elotuzumab is an anti-SLAMF7 monoclonal antibody that is FDA-approved for the treatment of multiple myeloma (68, 69), raising the possibility that such drugs could also be used in the treatment of EBV-associated tumors with high SLAMF7 expression. The gene discussed is SLAMF7; the disease is plasma cell myeloma.